Article
Biochemistry & Molecular Biology
Yu Yan, Athira Narayan, Soonweng Cho, Zhiqiang Cheng, Jun O. Liu, Heng Zhu, Guannan Wang, Bryan Wharram, Ala Lisok, Mary Brummet, Harumi Saeki, Tao Huang, Kathleen Gabrielson, Edward Gabrielson, Leslie Cope, Yasmine M. Kanaan, Ali Afsari, Tammey Naab, Harris G. Yfantis, Stefan Ambs, Martin G. Pomper, Saraswati Sukumar, Vanessa F. Merino
Summary: CRY beta B2 is upregulated in breast tumors of African American patients, leading to malignancy and decreased survival. This protein enhances the stemness and metastatic properties of breast cancer cells by activating multiple signaling pathways.
Article
Oncology
Zhitao Han, Qi Jia, Jing Zhang, Miaomiao Chen, Lining Wang, Kai Tong, Weiwei He, Yajie Zhang, Weina Zhu, Ju Qin, Tao Wang, Tielong Liu, Yong Ma, Yuanming Chen, Siluo Zha, Chunlei Zhang
Summary: YOD1 is significantly upregulated in TNBC tissues and is positively correlated with poor survival in TNBC patients. YOD1 plays an oncogenic role in TNBC by binding to CDK1 and mediating its stability and oncogenic activity. Interfering with YOD1 expression or using YOD1 inhibitors can suppress TNBC cells in vitro and in vivo, suggesting that YOD1 may be a promising therapeutic target for TNBC.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Sara Caetano, Ana Rita Garcia, Ines Figueira, Maria Alexandra Brito
Summary: This study reveals the involvement of miR-194-5p and MEF2C in TNBC tumorigenesis. It is found that downregulation of miR-194-5p and upregulation of MEF2C are associated with TNBC brain metastasis development. Silencing MEF2C reduces TNBC cells' epithelial-mesenchymal transition and migration capability, while overexpressing miR-194-5p promotes an epithelial phenotype and decreases the aggressiveness of TNBC cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Nutrition & Dietetics
Getinet M. Adinew, Equar Taka, Patricia Mendonca, Samia S. Messeha, Karam F. A. Soliman
Summary: Flavonoids, as new promising molecules, show various biological activities and can modulate miRNAs to affect the progression of TNBC, emphasizing their potential role in the prevention and treatment of TNBC.
Letter
Medicine, General & Internal
Ryan Sun, Lee-Jen Wei
Summary: This article discusses the clinical benefits of pembrolizumab combined with chemotherapy in patients with triple-negative breast cancer. The authors suggest that both hazard values and ratios should be considered when evaluating clinical benefits.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Cell Biology
Shuyan Han, Huifeng Hao, Haibo Han, Dong Xue, Yanna Jiao, Yuntao Xie, Ye Xu, Longtao Huangfu, Jialei Fu, Shan Wang, Hong Sun, Pingping Li, Qun Zhou
Summary: CUEDC2 plays a crucial role in the hyperactivation of Wnt signaling and tumorigenesis in triple-negative breast cancer (TNBC). It enhances Wnt signaling by directly binding to β-catenin and promoting its nuclear translocation. Targeting the interaction between CUEDC2 and β-catenin may be a promising strategy for combating TNBC.
Article
Pathology
Dan Xie, Saiyang Li, Tianqi Wu, Xuehui Wang, Lin Fang
Summary: Breast cancer is the most common cancer in women worldwide, and triple negative breast cancer is a highly aggressive subtype of breast cancer. This study demonstrates that miR-181c inhibits the proliferation and migration of triple negative breast cancer cells, promotes apoptosis, and regulates the cell cycle. Importantly, miR-181c suppresses the tumor-promoting effect of MAP4K4 by targeting its expression.
PATHOLOGY RESEARCH AND PRACTICE
(2022)
Article
Cell Biology
Mengqin Shen, Ruixue Zhang, Wenzhi Jia, Zongping Zhu, Li Zhao, Gang Huang, Jianjun Liu
Summary: This study reveals the association of nuclear EGFR with RNA-binding proteins (RBPs) and identifies NONO as a key RBP in TNBC. NONO is upregulated in TNBC tissues and enhances EGFR transcriptional activity by increasing its stability and recruiting specific proteins. Moreover, the nuclear EGFR/NONO complex plays a critical role in tumorigenesis and chemotherapy resistance in TNBC.
CELL DEATH & DISEASE
(2022)
Article
Cell Biology
Anli Yang, Fu Peng, Lewei Zhu, Xing Li, Shunling Ou, Zhongying Huang, Song Wu, Cheng Peng, Peng Liu, Yanan Kong
Summary: Melatonin treatment downregulated FUNDC1 and lnc049808 in TNBC cell lines, which inhibited cell proliferation, invasion, and metastasis. lnc049808 and FUNDC1 acted as competing endogenous RNAs binding to miR-101, indicating a potential therapeutic pathway for TNBC progression inhibition by melatonin.
CELL DEATH & DISEASE
(2021)
Article
Biochemistry & Molecular Biology
Riccardo Panella, Cody A. Cotton, Valerie A. Maymi, Sachem Best, Kelsey E. Berry, Samuel Lee, Felipe Batalini, Ioannis S. Vlachos, John G. Clohessy, Sakari Kauppinen, Pier Paolo Pandolfi
Summary: In this study, it was found that miR-22, an oncogenic miRNA, is up-regulated in hormone-responsive breast cancer and promotes EMT, tumor invasion, and metastasis. In triple negative breast cancer (TNBC), miR-22 plays a key role in promoting EMT and aggressiveness. Inhibition of miR-22 using an LNA-modified compound effectively reduces EMT both in vitro and in vivo, providing a potential therapeutic strategy for TNBC treatment.
Article
Medicine, Research & Experimental
Qiancheng He, Qiongyu Hao, Yanyuan Wu, Jaydutt V. Vadgama, Yiyan Jiang
Summary: The long-term prognosis for breast cancer patients with metastasis is very poor, and genetic alterations in tumor cells lead to cellular heterogeneity, promoting cancer cell invasion and colonization. CircRNAs play an important role in identifying disease mechanisms and developing effective treatments. However, the role of aberrant circRNA expression in breast cancer progression is still largely unknown.
Letter
Medicine, General & Internal
Shuvadeep Ganguly, Ajay Gogia
Summary: In the KEYNOTE-522 trial, the addition of Pembrolizumab to neoadjuvant chemotherapy improved pathological complete response rate in early triple-negative breast cancer patients and also improved event-free survival. However, this improvement was predominantly observed in patients who did not achieve a pathological complete response.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Xin Guo, Aman Wang, Wen Wang, Ya Wang, Huan Chen, Xiaolong Liu, Tian Xia, Aijia Zhang, Di Chen, Huan Qi, Ting Ling, Hai-long Piao, Hong-jiang Wang
Summary: Dependence on glutamine and acceleration of fatty acid oxidation are metabolic characteristics of triple-negative breast cancer. HRD1 acts as a regulatory protein for FAO, inhibiting TNBC cell proliferation under glutamine-deficient conditions. This finding provides insight into HRD1 as a regulator of lipid metabolism for potential therapeutic targeting in TNBC.
MOLECULAR ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Maram Almohaywi, Bruna M. Sugita, Ariana Centa, Aline S. Fonseca, Valquiria C. Antunes, Paolo Fadda, Ciaran M. Mannion, Tomilowo Abijo, Stuart L. Goldberg, Michael C. Campbell, Robert L. Copeland, Yasmine Kanaan, Luciane R. Cavalli, Tiziana Squillaro, Mauro Finicelli
Summary: Studies suggest that deregulated miRNA expression in TNBC patients may correlate with aggressive phenotype. A panel of 28 miRNAs associated with copy number alterations were identified in TNBC biopsies from Latina women, with miR-182-5p being the most discriminatory. Up-regulation of miR-141-3p was linked to increased cancer recurrence, while down-regulation of miR-661 and miR-150-5p were associated with larger tumor size and other clinical factors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Soo Jung Lee, Jae-Hwan Jeong, Jeeyeon Lee, Ho Yong Park, Jin Hyang Jung, Jieun Kang, Eun Ae Kim, Nora Jee-Young Park, Ji-Young Park, In Hee Lee, Yee Soo Chae
Summary: The study indicates that miR-496 and miR-137 may modulate the progression of triple negative breast cancer (TNBC) by targeting the Del-1 gene, potentially serving as new biomarkers for patients with TNBC.
Article
Oncology
M. D. Matossian, T. Chang, M. K. Wright, H. E. Burks, S. Elliott, R. A. Sabol, H. Wathieu, G. O. Windsor, M. S. Alzoubi, C. T. King, J. B. Bursavich, A. M. Ham, J. J. Savoie, K. Nguyen, M. Baddoo, E. Flemington, O. Sirenko, E. F. Cromwell, K. L. Hebert, F. Lau, R. Izadpanah, H. Brown, S. Sinha, J. Zabaleta, A. Riker, K. Moroz, L. Miele, A. H. Zea, A. Ochoa, B. A. Bunnell, B. M. Collins-Burow, E. C. Martin, M. E. Burow
Summary: This study introduces an innovative translational model system to study cell-matrix interactions in rare cancer types, using higher passage PDX tissue.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Samuel C. Okpechi, Hassan Yousefi, Khoa Nguyen, Thomas Cheng, Nikhilesh Alahari, Bridgette Collins-Burow, Matthew E. Burow, Suresh K. Alahari
Summary: This review comprehensively discusses the role and relevance of Nischarin in breast cancer. The expression level of Nischarin gene and its correlation with patient survival, disease characteristics, and EMT-related genes are analyzed. The results suggest that Nischarin plays a critical role in the initiation and progression of breast cancer.
Article
Biochemical Research Methods
Evan F. Cromwell, Oksana Sirenko, Ekaterina Nikolov, Matthew Hammer, Courtney K. Brock, Margarite D. Matossian, Madlin S. Alzoubi, Bridgette M. Collins-Burow, Matthew E. Burow
Summary: 3D cell models derived from patient tumors can recapitulate the complex genetic and molecular compositions of solid cancers, making them valuable tools for drug target identification and drug testing. However, using these models for assays is still challenging. In this study, the authors describe methods for processing and multi-functional profiling of tumoroids to test compound effects using a novel flowchip system. The results provide an in-depth understanding of the drug sensitivity of individual tumor types, with important implications for personalized medicine.
Article
Biochemistry & Molecular Biology
Rashidra R. Walker, Jankiben R. Patel, Akash Gupta, A. Michael Davidson, Christopher C. Williams, Florastina Payton-Stewart, Stephen M. Boue, Matthew E. Burow, Rahul Khupse, Syreeta L. Tilghman
Summary: The combination treatment of glyceollins and lapatinib could reduce the proliferation of hormone-dependent letrozole-resistant breast cancer cells by inducing apoptosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell & Tissue Engineering
Katie M. Hamel, Connor T. King, Maryn B. Cavalier, Kara Q. Liimatta, Grace L. Rozanski, Timothy A. King, Meggie Lam, Grace C. Bingham, C. Ethan Byrne, Diensn Xing, Bridgette M. Collins-Burow, Matthew E. Burow, Jorge A. Belgodere, Melyssa R. Bratton, Bruce A. Bunnell, Elizabeth C. Martin
Summary: Adipose tissue acts as an endocrine organ and its signals contribute to the progression of breast cancer. Young breast tumors have more matrix and paracrine factors compared to aged tumors. Factors produced by young adipose tissue enhance the endocrine response in breast cancer cells.
STEM CELLS AND DEVELOPMENT
(2022)
Article
Oncology
Alifiani Bonita Hartono, Hong-Jun Kang, Lawrence Shi, Whitney Phipps, Nathan Ungerleider, Alexandra Giardina, WeiPing Chen, Lee Spraggon, Romel Somwar, Krzysztof Moroz, David H. Drewry, Matthew E. Burow, Erik Flemington, Marc Ladanyi, Sean Bong Lee
Summary: Desmoplastic Small Round Cell Tumor (DSRCT) is a rare and aggressive malignant cancer caused by a chromosomal translocation. The study identified SIK1 as a direct target of the oncogenic transcription factor EWSR1-WT1, and depletion of SIK1 inhibited tumor cell growth and DNA replication. Combined inhibition of SIK1 and CHEK1 showed enhanced cytotoxicity in DSRCT cells.
Article
Biochemistry & Molecular Biology
Jankiben R. Patel, Prasad Thangavelu, Renee M. Terrell, Bridg'ette Israel, Arindam Basu Sarkar, A. Michael Davidson, Kun Zhang, Rahul Khupse, Syreeta L. Tilghman
Summary: A novel allosteric inhibitor targeting the PLK1 T-loop was developed and shown to have anti-proliferative and anti-migratory properties in triple-negative breast cancer cells. The inhibitor caused cell cycle arrest and increased p21 expression, suggesting its potential as a promising approach for TNBC treatment.
Article
Endocrinology & Metabolism
Fahima Munmun, Omair A. Mohiuddin, Van T. Hoang, Matthew E. Burow, Bruce A. Bunnell, Veronica M. Sola, Agata R. Carpentieri, Paula A. Witt-Enderby
Summary: This study demonstrates for the first time the role of MEK1/2 and MEK5 in modulating melatonin-mediated actions on bone formation in vivo and in a sex-specific manner.
JOURNAL OF PINEAL RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Shengli Dong, Hassan Yousefi, Isabella Van Savage, Samuel C. Okpechi, Maryl K. Wright, Margarite D. Matossian, Bridgette M. Collins-Burow, Matthew E. Burow, Suresh K. Alahari
Summary: Combination therapy with ceritinib and enzalutamide inhibits the growth of AR(+) TNBC cells, while combination therapy with ceritinib and paclitaxel drastically inhibits tumor growth. These findings suggest that combination treatment with these FDA-approved drugs can improve the therapeutic response in both AR-positive and negative breast cancer.
Article
Biochemistry & Molecular Biology
Connor T. King, Margarite D. Matossian, Jonathan J. Savoie, Khoa Nguyen, Maryl K. Wright, C. Ethan Byrne, Steven Elliott, Hope E. Burks, Melyssa R. Bratton, Nicholas C. Pashos, Bruce A. Bunnell, Matthew E. Burow, Bridgette M. Collins-Burow, Elizabeth C. Martin
Summary: In this study, the role of liver kinase B1 (LKB1) in regulating the tumor microenvironment was evaluated. Results showed that LKB1 affects tumorigenesis and metastasis by altering matrix protein production and inhibiting adipogenesis. LKB1 overexpression decreases collagen production and suppresses tumor-mediated adipogenesis.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2022)
Review
Oncology
Bruce A. Bunnell, Elizabeth C. Martin, Margarite D. Matossian, Courtney K. Brock, Khoa Nguyen, Bridgette Collins-Burow, Matthew E. Burow
Summary: The increase in obesity has led to more adipose stromal/stem cells (ASCs) in the body, which have been shown to impact cancer progression. Obesity-induced alterations in the biological properties of ASCs contribute to enhanced tumorigenesis and metastasis of cancer cells. The interaction between obesity and ASCs plays a role in the development and aggressiveness of various cancers.
CANCER AND METASTASIS REVIEWS
(2022)
Article
Nutrition & Dietetics
Jankiben R. Patel, Bipika Banjara, Afia Ohemeng, A. Michael Davidson, Stephen M. Boue, Matthew E. Burow, Syreeta L. Tilghman
Summary: Breast cancer cells that become resistant to letrozole overexpress EGFR, MAPK, and HER2, while also acquiring enhanced motility and EMT-like characteristics, which can be attenuated and reversed by glyceollin treatment. Glyceollin inhibits the proliferation and tumor progression of TNBC and estrogen-independent breast cancer cells, but it may not effectively target AI-resistant metastatic breast cancer in clinical settings. Combination therapy of glyceollin and lapatinib induces apoptosis in hormone-dependent AI-resistant breast cancer cells, and it may also be beneficial for letrozole-resistant breast cancer cells by decreasing proliferation and cell cycle progression-associated proteins. This unique opportunity could lead to the development of novel combination therapies for hormone-refractory breast tumors.
Meeting Abstract
Oncology
Oksana Sirenko, Angeline Lim, Courtney K. Brock, Katya Nikolov, Cathy Olsen, Evan F. Cromwell, Margarite D. Matossian, Matthew E. Burow
Article
Oncology
Khoa Nguyen, Emily McConnell, Orielle Edwards, Bridgette M. Collins-Burow, Matthew E. Burow
Summary: This article discusses the issue of resistance in breast cancer therapies, with a focus on the cancer stem cell subpopulation and their mechanisms for resistance.
CANCER DRUG RESISTANCE
(2022)
Meeting Abstract
Medicine, General & Internal
C. Brock, M. Wright, K. Nguyen, T. Cheng, B. Collins-Burow, B. Bunnell, M. Burow
JOURNAL OF INVESTIGATIVE MEDICINE
(2022)
